Connecting to LinkedIn...

W1siziisijiwmtuvmdqvmtuvmdgvntqvmzgvnzi1l01ptlrbu0hfqkxpr19vtljftkrfukvex0lnqudfx3jlc2l6zwrfyw5kx3jlbmrlcmvklmpwzyjdlfsiccisinrodw1iiiwimtkymhgxmjuwiyjdxq

Blog

Early trial results of heart drug suggests Novartis has a winner on its hands

1/04/2014 by

W1siziisijiwmtqvmtavmjgvmtuvndyvndavmtc0l2zpbguixsxbinailcj0ahvtyiisijywmhg0mdbcdtawm2uixv0


Novartis has started the week on a high note, with the pharmaceutical company announcing its plans to terminate a drug trial ahead of schedule. The decision was made on the unanimous recommendation of an independent committee, with the company now seeking approval on the basis of the drug’s positive results thus far.

The drug, LCZ696, was recommended after early results showed that patients trialling it lived longer – and without hospitalization – than patients taking enalapril. Designed to treat heart failure, Novartis is going to present the findings and the case for approval at an upcoming meeting with various global health authorities. Milton Packer, co-Principal investigator of trial, confirmed that the evidence in LCZ696′s favor was indeed strong enough to warrant stopping the trial. “The stopping rule was not on the primary endpoint, it was on cardiovascular death,” he said to Forbes’ Larry Husten. “It was a stopping rule that required a very high level of statistical significance for early termination.”

The news comes in contrast to last week’s response to Serelaxin, another Novartis drug that the U.S. Food and Drug Administration (FDA) turned down for approval. Also intended to treat heart disease, Serelaxin did not present a strong enough case, with minimal evidence to support its claims. Earlier this year, a European advisory committee cast similar judgement, limiting Serelaxin’s future in cardiac medicine.

This article has been extracted from http://www.techtimes.com, please click on this link to read the article in full http://www.techtimes.com/articles/5031/20140331/early-trial-results-of-heart-drug-suggests-novartis-has-a-winner-on-its-hands.htm

Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:

ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.

With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.

For more information please visit www.montash.com

comments powered by Disqus

Social Stream

Latest News

W1siziisijiwmtcvmduvmjmvmtmvmjavmjkvndg3l3nodxr0zxjzdg9ja180mtqwnti1mdeuanbnil0swyjwiiwidgh1bwiilcizodb4mtawiyjdxq

Their Shoes... Matthew Gilbranch, Managing C...

2017-05-23 15:00:00 +0100

Matthew Gilbranch (32) is a managing consultant here at Montash, managing the SAP team. With 7 years in the global recruitment industry, he loves helping people and building lasting relationships with clients and candidates alike. He took the time to talk to us about what a typical day is like in the global IT recruitment industry. "I get up at 6 and I'm out of the house by half 6 and on the train by twenty to 7. On the train I tend to have a power nap ...

W1siziisijiwmtcvmduvmdqvmtyvndavmzkvotg5l3nodxr0zxjzdg9ja181ndm0mduxmtuuanbnil0swyjwiiwidgh1bwiilcizodb4mtawiyjdxq

7 Things About Your CV You Need To Fix Right ...

2017-05-04 18:00:00 +0100

As a global technology recruitment agency, we are in touch with candidates day in and day out. We've seen all kinds of CVs in our time and know a good one when we see it. As our recruitment team look to find the ideal candidate, they are looking for CVs that show how candidates can impact their clients in a positive way, not just look flashy on paper. You only have a small amount of space on your CV to show off your skills, so make every word count. Cut...